All In Biotech

Drug Trial Radar · NCT05602597

HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI

A Phase 1, Open-Label, 4-Part, Fixed-Sequence Study to Assess the Effect of Itraconazole, a Strong CYP3A Inhibitor, the Effect of Fluconazole, a Moderate CYP3A/2C9 Inhibitor, the Effect of Rifampin, a Strong CYP3A Inducer, and the Effect of Rabeprazole, a Proton Pump Inhibitor on the Pharmacokinetics of HMPL-689 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Mar 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

59

Actual

Start

Jun 1, 2022

Primary completion

Aug 6, 2022

Study completion Aug 6, 2022

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Nov 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An open-label study to determine effect of Itraconazole, Fluconazole, Rifampin, and Rabeprazole on the PK of HMPL-689

Conditions

  • Relapsed or Refractory Lymphoma

Interventions

  • Itraconazole 200 mgDrug

    Study participants will be administered 200 mg itraconazole by mouth twice daily after the pharmacokinetic blood draw on Day 3 and once daily on Days 4 to 10, inclusive.

  • Fluconazole 400 mgDrug

    Study participants will be administered 400 mg fluconazole by mouth daily on Day 3 after the pharmacokinetic blood draw, and 200 mg fluconazole by mouth daily on Days 4 to 10, inclusive.

  • Rifampin 600 mgDrug

    Study participants will be administered 600 mg rifampin by mouth daily starting on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 11, inclusive.

  • Rabeprazole 40 mgDrug

    Study participants will be administered 40 mg rabeprazole by mouth daily on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 9, inclusive.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC0-tTime frame: From Day 1 to Day 11 (Day 12 for Rifampin)
  2. AUC0-infTime frame: From Day 1 to Day 11 (Day 12 for Rifampin)
  3. CmaxTime frame: From Day 1 to Day 11 (Day 12 for Rifampin)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • QPS- Miami

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.